Influenza Vaccine for the 2019-2020 Season
Cumulative 2019/2020 Season Lot Release Status (Updated 12/5/2019)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.
| Manufacturer | Total Number of Lots Released by FDA |
|---|---|
| Afluria Quadrivalent Seqirus Pty. Ltd. |
66 |
| Fluad Seqirus, Inc. |
16 |
| Fluarix Quadrivalent GlaxoSmithKline Biologicals |
46 |
| Flublok Quadrivalent Protein Sciences Corporation |
73 |
| Flucelvax Quadrivalent Seqirus, Inc. |
52 |
| FluLaval Quadrivalent ID Biomedical Corporation of Quebec |
35 |
| FluMist Quadrivalent MedImmune, LLC |
3 |
| Fluzone High Dose Sanofi Pasteur, Inc. |
32 |
| Fluzone Quadrivalent Sanofi Pasteur, Inc. |
34 |
FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2018-2019 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2019-2020 influenza season contain the following:
- an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
- an A/Kansas/14/2017 (H3N2)-like virus;
- a B/Colorado/06/2017-like virus (B/Victoria lineage).
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
- a B/Phuket/3073/2013-like virus (B/Yamagata lineage)